electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
7.52
-0.59 (-7.27%)
At close: Oct 30, 2026, 4:00 PM EDT
7.53
+0.01 (0.12%)
After-hours: Oct 30, 2026, 7:43 PM EDT
electroCore Revenue
electroCore had revenue of $9.45M in the quarter ending June 30, 2026, with 28.03% growth. This brings the company's total for the last twelve months to $36.97M, up 33.45% year-over-year. In the year 2025, electroCore had annual revenue of $32.03M with 27.20% growth. That makes electroCore the 30,028th largest company in the world by revenue and 3,982nd in the United States.
Revenue (ttm)
$36.97M
Revenue Growth
+33.45%
P/S Ratio
1.83
Revenue / Employee
$445,373
Employees
83
Market Cap
67.80M
Revenue by Geography
- United States 30.08M 93.9%
- United Kingdom 1.70M 5.3%
- Other 197.00K 0.6%
- Japan 65.00K 0.2%
Fiscal year ended Dec 31, 2025 See the full electroCore breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.03M | 6.85M | 27.20% |
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | 2.39M | 1.40M | 140.72% |
| Dec 31, 2018 | 992.95K | 181.50K | 22.37% |
| Dec 31, 2017 | 811.46K | 557.32K | 219.30% |
| Dec 31, 2016 | 254.14K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Outset Medical | 117.80M |
| LENSAR | 60.26M |
| Myomo | 43.26M |
| Nyxoah | 24.75M |
| Sensus Healthcare | 17.51M |
| Hyperfine | 16.54M |
| Spectral AI | 15.39M |
| Lucid Diagnostics | 5.45M |
ECOR News
- 3 days ago - electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 - GlobeNewsWire
- 4 days ago - electroCore Transcript: Planet MicroCap Showcase: Toronto 2026 - Transcripts
- 4 days ago - electroCore submits 510 premarket notification to FDA for Quell - TheFly
- 4 days ago - electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) - GlobeNewsWire
- 5 days ago - fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning - GlobeNewsWire
- 11 days ago - electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub - GlobeNewsWire
- 7 weeks ago - electroCore to Participate at H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 7 weeks ago - electroCore appoints Joshua Lev, Mike Fox as co-CEOs - TheFly